{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/rheumatoid-arthritis/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"7eba8b39-2fb0-52b0-8988-5d108c1720fa","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 9f2b5885-6c9a-4ad3-8571-ab150126202f --><h2>Changes</h2><!-- end field 9f2b5885-6c9a-4ad3-8571-ab150126202f -->","summary":null,"htmlStringContent":"<!-- begin item 76e2cb0e-c409-44a7-bbe7-5bcda2eddcfa --><!-- begin field fb33c504-4a3c-4192-a351-ae5ad000f2cb --><p><strong>April 2020 </strong>— minor update. New management scenario created to provide information regarding COVID-19. </p><p><strong>January 2020</strong> — minor update. Quality standards updated. </p><p><strong>December 2018 to January 2019 </strong>— reviewed. A literature search was conducted in December 2018 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic.</p><!-- end field fb33c504-4a3c-4192-a351-ae5ad000f2cb --><!-- end item 76e2cb0e-c409-44a7-bbe7-5bcda2eddcfa -->","topic":{"id":"80425c66-11ed-5a54-aecf-455f339cb0cd","topicId":"d9596563-d663-48ca-8d6a-4ddeb263b46e","topicName":"Rheumatoid arthritis","slug":"rheumatoid-arthritis","lastRevised":"Last revised in April 2020","chapters":[{"id":"e5b4cb7c-c830-59e0-a369-a8151bd28e7c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"28d53d37-f5b2-5ab0-bd6f-6c6858fc63e4","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"8eb76d85-83a8-5bb1-be89-15a9e86def8d","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"7eba8b39-2fb0-52b0-8988-5d108c1720fa","slug":"changes","fullItemName":"Changes"},{"id":"add57644-4b68-5377-b8ce-b0cc395570f0","slug":"update","fullItemName":"Update"}]},{"id":"62d68b4b-4522-5afb-88fe-48b87fc31a2d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f9fe7005-bf48-5a4e-bc7c-08550e792a18","slug":"goals","fullItemName":"Goals"},{"id":"cc0b2b43-25e2-5936-ad94-217419fd0126","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6a0fead6-ca32-5399-9b1b-22b31fc0c765","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f76001a5-99f4-5086-bc05-c1cd7535aab0","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"fb29501f-d465-5652-b659-ffb4e5c8e928","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"3181265d-dee9-5587-974d-b4bae95c10ee","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"167941e5-411a-5afd-94af-8e7725b24b1a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"bb48f4e9-23c4-5828-bccb-666f4dbc512d","slug":"definition","fullItemName":"Definition"},{"id":"06cc7595-3f6c-59d6-929b-964159afde4d","slug":"prevalence-incidence","fullItemName":"Prevalence and incidence"},{"id":"8fb1fc93-039a-5d6b-a86d-aeb61578f11d","slug":"complications","fullItemName":"Complications"}]},{"id":"e352008d-7a0c-55ba-b778-c6218ef4ef69","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"b9d257ab-0ebb-52bf-908a-8ebebe6c550c","slug":"when-to-suspect-ra","fullItemName":"When to suspect RA"},{"id":"25d80dc3-ea8a-5560-8a0b-3a64b87c5690","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"5de822df-3081-5ed6-a21b-e3e2925436bd","slug":"investigations-for-suspected-ra","fullItemName":"Investigations for suspected RA"}]},{"id":"6f1e7941-f462-5d64-8822-8328310b81b9","fullItemName":"Management","slug":"management","subChapters":[{"id":"2ed609a5-1052-56f5-b263-63d4e5325949","slug":"suspected-ra","fullItemName":"Scenario: Suspected RA"},{"id":"0ba5ec6e-3f0f-5157-8e24-55ef24b2cfe9","slug":"confirmed-ra","fullItemName":"Scenario: Confirmed RA"},{"id":"c490cb4d-f228-5c81-b9f2-0ac419b6d60a","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"13cb1ed1-b962-5e8a-88c8-8b7185af06df","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"e875cc8d-258b-5535-9d34-40f03cb150c7","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"9b45cf27-1cfb-591d-a936-5e49910f88ac","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"93bd3cb0-31a7-5acf-bc5f-8858b54e466b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"a24a6436-a685-5277-8c22-524ebe895154","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4258a438-16bd-591d-bd95-5d6a682e1696","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"58298e48-e237-5259-b79b-da11e96f0a4e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"6c1abdea-39c1-5537-8e4f-6e6ff3a71736","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"8eb76d85-83a8-5bb1-be89-15a9e86def8d","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"e87f66f7-e7b0-549d-ac6d-32b22f714806","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 6eeb0f7d-1b8f-45fe-aa3f-cb0e1c1f7dcb --><h3>Previous changes</h3><!-- end field 6eeb0f7d-1b8f-45fe-aa3f-cb0e1c1f7dcb -->","summary":null,"htmlStringContent":"<!-- begin item 02f2ac92-37fc-4442-bc37-0974a279d39a --><!-- begin field 06949914-fc8d-4c5f-8478-c8845fedce0a --><p><strong>December 2018</strong> — minor update. Advice on when to refer patients with persistent synovitis changed from 2 weeks to within 3 working days of presentation. </p><p><strong>July 2018</strong> — minor update. NICE quality standards added. </p><p><strong>August 2013 </strong>— reviewed. A literature search was conducted in August 2013 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of this topic. No major changes to recommendations have been made.</p><p><strong>July 2013 </strong>— minor update. Update to the text to reflect recent advice from the MHRA regarding diclofenac.</p><p><strong>February 2013 </strong>— minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><strong>October 2012 </strong>— minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>August 2011 </strong>— minor update. References to the SIGN guideline on <em>Management of early rheumatoid arthritis </em>(2000) have been updated to the 2011 version. Minor text change to the <em>Definition</em> node. Issued in September 2011.</p><p><strong>May 2011 </strong>— minor update. The 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011.</p><p><strong>June 2010 </strong>— minor update. In people at risk of cardiovascular adverse events, ibuprofen up to 1200 mg per day or naproxen up to 1000 mg per day are recommended as first-line NSAIDs. Issued in July 2010.</p><p><strong>December 2009 </strong>— minor update. Triamcinolone acetonide (Kenalog<sup>®</sup>) pre-filled syringes have been discontinued. Prescription replaced with triamcinolone acetonide 40 mg/1 mL vials. Issued in December 2009.</p><p><strong>March to June 2009 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. There are no major changes to the recommendations.</p><p><strong>September 2008 </strong>— minor correction to the <em>Changes </em>section. Issued September 2008.</p><p><strong>July 2006 </strong>— minor update to drug rationales. Issued in July 2006.</p><p><strong>October 2005 </strong>— minor technical update. Issued in November 2005.</p><p><strong>July 2005 </strong>— update to the <em>Medicines management </em>sections on nonsteroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs). Issued in July 2005.</p><p><strong>April 2005 </strong>— minor update to include new advice from the Committee on Safety of Medicines (CSM) on the safety of COX-2 selective inhibitors. Issued in April 2005.</p><p><strong>September 2004 </strong>— rewritten. Validated in November 2004 and issued in February 2005.</p><p><strong>June 2004 </strong>— updated to include reference to the National Institute for Health and Care Excellence (NICE) technology appraisal no. 72. <em>Anakinra for rheumatoid arthritis</em>. Validated in September 2004.</p><p><strong>February 2004 </strong>— updated to incorporate safety advice from the Committee of Safety of Medicines (CSM) on the use of hormone replacement therapy (HRT) for osteoporosis.</p><p><strong>March 2002 </strong>— updated to include reference to the National Institute for Health and Care Excellence (NICE) technology appraisal no.36. <em>Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis.</em></p><p><strong>November 2001 </strong>— reviewed, and in particular incorporating recommendations from the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Management of early rheumatoid arthritis</em>.</p><p><strong>July 1999 </strong>— written. Validated in October 1999 and issued in January 2000.</p><!-- end field 06949914-fc8d-4c5f-8478-c8845fedce0a --><!-- end item 02f2ac92-37fc-4442-bc37-0974a279d39a -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}